ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective by Tsaioun, Katya et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Neurology
Open Access Proceedings
ADDME – Avoiding Drug Development Mistakes Early: central nervous 
system drug discovery perspective
Katya Tsaioun*1, Michel Bottlaender2, Aloise Mabondzo3 for the Alzheimer's 
Drug Discovery Foundation
Address: 1Apredica, 313 Pleasant Street, Watertown, MA 02472, USA, 2CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, 91401, France and 
3CEA, iBiTec-S, Service de Pharmacologie et d'ImmunoAnalyse, Gif-sur-Yvette, 91191, France
Email: Katya Tsaioun* - Katya@Apredica.com; Michel Bottlaender - Michel.bottlaender@cea.fr; Aloise Mabondzo - Aloise.mabondzo@cea.fr; 
the Alzheimer's Drug Discovery Foundation - not@valid.com
* Corresponding author    
Abstract
The advent of early absorption, distribution, metabolism, excretion, and toxicity (ADMET)
screening has increased the attrition rate of weak drug candidates early in the drug-discovery
process, and decreased the proportion of compounds failing in clinical trials for ADMET reasons.
This paper reviews the history of ADMET screening and its place in pharmaceutical development,
and central nervous system drug discovery in particular. Assays that have been developed in
response to specific needs and improvements in technology that result in higher throughput and
greater accuracy of prediction of human mechanisms of absorption and toxicity are discussed. The
paper concludes with the authors' forecast of new models that will better predict human efficacy
and toxicity.
Introduction
The goal of this paper, which was presented at the Alzhe-
imer's Drug Discovery Foundation conference in Wash-
ington, DC on 3 February 2009 [1] is to briefly review
advances in the science of predicting human absorption,
distribution, metabolism, excretion and toxicity
(ADMET) from in vitro and in vivo models, to review pres-
ently available assays as well as those in the process of
being validated, and to present a model for designing
effective  in vitro ADMET programs that are used to
advance drug-development programs at the lead-optimi-
zation and preclinical candidate selection stages.
Drug attrition late in clinical development or involving
those already on the market is a serious economic prob-
lem in the pharmaceutical industry [2]. The cost of getting
a drug to market is approaching US$1 billion and the cost
of advancing a compound to phase I trials can reach up to
US$100 million according to the Tufts Center for the
Study of Drug Development, Tufts University School of
Medicine [3]. The study also estimates that each day a
drug is in the development stage costs US$37,000 in
direct out-of-pocket costs and represents opportunity
costs of US$1.1 million in lost revenue [3]. Given these
huge expenditures, substantial savings can accrue from
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early recognition of problems that would make a com-
pound unlikely to succeed in development [4].
The costs associated with withdrawing a drug from the
market are even higher. For example, consider the case of
terfenadine, which is a potent hERG ligand and is metab-
olized by Cyp3A4. Terfenadine was frequently co-admin-
istered with ketoconazole or erythromycin [5], both of
which are Cyp3A4 inhibitors. The consequent overload
resulted in increases in plasma terfenadine to levels that
caused cardiac toxicity [6]. This toxicity caused terfena-
dine to be withdrawn from the market [7] at an estimated
cost of US$6 billion. Another example is the broad-spec-
trum antibiotic trovafloxacin, which was introduced in
1997 and soon became Pfizer's top seller. It is metaboli-
cally activated in vivo and forms a highly reactive metabo-
lite, which resulted in severe drug-induced hepatotoxicity
[8]. Trovafloxacin was black labeled in 1998 [9], poten-
tially costing Pfizer US$8.5 billion in lawsuits [10]. With
the ADMET assays now available, the liabilities associated
with these drugs could have been recognized in early pre-
clinical development.
The purpose of preclinical ADMET is to eliminate weak
candidates. This allows drug-development resources to be
focused on fewer but more-likely-to-succeed drug candi-
dates. In 1993, 40% of drugs failed in clinical trials
because of pharmacokinetics (PK) and bioavailability
problems [11]. Since then, major technological advances
have occurred in molecular biology and screening to
allow major aspects of ADMET to be assessed much ear-
lier, at the lead-optimization stage. By the late 1990s the
pharmaceutical industry as a whole recognized the value
of early ADMET assessment and began routinely employ-
ing it. The results were striking. ADME and drug metabo-
lism PK reasons for failure fell from 40% to 11% [4]. Now,
lack of efficacy and human toxicity are the major reasons
for failure [12].
The terms 'drugability' and 'druglikeness' were coined by
Dr Christopher Lipinski, who also proposed what has
come to be known as Lipinski's 'Rule of 5' due to the fre-
quent appearance of '5' in the rules [13]. The Rule of 5 has
come to be a compass for the drug discovery industry [14].
It stipulates that small-molecule drug candidates must
have: a molecular weight less than 500 g/mol; a partition
coefficient (logP – a measure of hydrophobicity) less than
5; no more than 5 hydrogen bond donors; no more than
10 hydrogen bond acceptors. A compound with fewer
than three of these properties is unlikely to become an
orally bioavailable drug. It is worth noting here that there
are exceptions to Lipinski's Rule of 5 that have become
marketed drugs, such as drugs that are taken up by active
transport mechanisms, natural compounds, oligonucle-
otides and proteins.
The drug-discovery industry is experiencing dramatic
structural change. It is no longer just the domain of tradi-
tional large pharmaceutical companies. Now venture-cap-
ital-funded startups, governments, venture philanthropy
and other nonprofit and academic organizations are sig-
nificant participants in the search for new drug targets,
pathways, and molecules. Thus, it is becoming increas-
ingly important to ensure that investors, donors, and tax-
payers' money is efficiently used so that new drugs for
unmet medical needs may be delivered to the public.
ADMET profiling has been proven to weed out poor drug
candidates and to speed discovery and development.
While lack of efficacy and unexpected toxicity are the
major causes of drug failure in clinical trials, as discussed
above, a prime determinant of both is how the drug pen-
etrates biological barriers such as the cell membrane,
intestinal wall, or blood-brain barrier (BBB). This is espe-
cially true in central nervous system (CNS) drugs, because
candidates that have in vitro efficacy but cannot penetrate
the BBB to reach targets in the brain are unlikely to have
in vivo efficacy in patients. Thus, the delivery of systemi-
cally administered drugs to the CNS of mammals is lim-
ited by the presence of the BBB, as the BBB effectively
isolates the brain from the blood because of the presence
of tight junctions connecting the endothelial cells of the
brain vessels. In addition, specific metabolizing enzymes
and efflux pumps, such as P-glycoprotein (P-gp) and the
multi-drug-resistance protein (MRP), located within the
endothelial cells, actively remove exogenous molecules
from the brain [15,16].
Hence, it is no coincidence that CNS drugs under develop-
ment have a notoriously high failure rate [17]. In recent
years, 9% of compounds that entered phase I survived to
launch, and only 3% to 5% of CNS drugs made it to mar-
ket [17]. Over 50% of this attrition resulted from failure to
demonstrate efficacy in phase II studies. Over the past dec-
ade, phase II failures have increased by 15%. Compounds
with demonstrated efficacy against the target in vitro and
in animal models have more often than not proved inef-
fective in human disease. Many of these failures may
occur due to drugs not reaching the CNS target because of
lack of BBB permeability.
Thus, given the extraordinary cost of new drug develop-
ment, it would be highly desirable to have effective, cost-
efficient high-throughput tools to measure BBB permea-
bility before proceeding to expensive compound- and
time-consuming animal BBB permeability studies or,
worse yet, failing in clinical trials. Correspondingly, with
such  in vitro tools, promising drug candidates without
effective BBB penetration could be improved at the earli-
est stages of development to increase intrinsic permeabil-
ity by, for example, removing structural components thatBMC Neurology 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2377/9/S1/S1
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mediate interaction(s) with efflux proteins, and/or lower-
ing binding to brain tissue [18].
The development of drugs targeting the CNS requires pre-
cise knowledge of the drug's brain penetration. Ideally,
this information would be obtained as early as possible to
focus resources on compounds most likely to reach the
target organ. The physical transport and metabolic com-
position of the BBB is highly complex. Numerous in vitro
models have been designed to study kinetic parameters in
the CNS, including non-cerebral peripheral endothelial
cell lines, immortalized rat brain endothelial cells, pri-
mary cultured bovine, porcine or rat brain capillary
endothelial cells and co-cultures of primary brain capil-
lary cells with astrocytes [19-21]. In vitro BBB models must
be carefully assessed for their capacity to reflect accurately
the passage of drugs into the CNS in vivo.
Alternatively, several in vivo experimental setups have
been used to estimate BBB passage of drugs directly in lab-
oratory animals. In vivo transport across the BBB was first
studied in the 1960s using the early indicator diffusion
method of Crone [22]. Other in vivo techniques were later
proposed: brain uptake index measurement [23], the in
situ brain perfusion method [24,25], and autoradiography
and intracerebral microdialysis [26] are in current use as
well. In spite of the sophisticated equipment, technical
expertise and mathematical modeling that these models
require, all of them have important limitations, notably
species differences and low throughput, as well as their
invasiveness. These limitations render them unsuitable
for use during early stages of drug discovery and develop-
ment.
Hence,  in vitro and  in vivo models alike remain mere
approximations of the complex human BBB, and their rel-
evance to the real life situation must be carefully consid-
ered. The most relevant way to conduct such controlled
experiments is to cross-compare the BBB passage of a
series of compounds evaluated with both in vitro and in
vivo models alongside each other. This enables cross-cor-
relations of PK data and the assessment of the predictive
power of in vitro and in vivo tests.
The evolving science of ADMET
Regulatory authorities have relied upon in vivo testing to
predict the behavior of new molecules in the human body
since the 1950s. Bioavailability, tissue distribution, PK,
metabolism, and toxicity are assessed in one rodent and
one non-rodent species before a drug may be tested in
human safety clinical trials (phase I).
Biodistribution is assessed using radioactively labeled
compounds later in development because it is expensive,
both in terms of synthesizing sufficient amounts of radio-
actively labeled compound and performing the animal
experiments [23].
Pharmacodynamic (PD) effectiveness of test compounds
is normally first assessed through in vitro models such as
receptor binding, followed by confirmation through in
vivo efficacy models in mice or rats. The predictive ability
of these models depends on the therapeutic area and the
model itself. Infectious disease models are considered to
have the best predictive ability, whereas CNS and oncol-
ogy animal models are generally the least predictive of
human efficacy. In vivo PK studies in a variety of animal
models are routinely used for lead optimization to assess
drug metabolism and absorption. Understanding the PK-
PD relationship is crucial in developing an understanding
of the mechanism of action and metabolic fate of a mole-
cule, which help to explain and support efficacy results.
However, there are significant differences in absorption
and metabolism among species. Animal studies alone,
therefore, may cause over- or under-prediction of absorp-
tion or metabolic degradation of new chemical entities
(NCEs).
Toxicity and safety studies are performed in models that
are relevant to an NCE's mode of action and therapeutic
area. In vivo toxicity models are required for an Investiga-
tional New Drug (IND) application to the US Food and
Drug Administration (FDA), but these have substantial
predictive weaknesses. In a retrospective study of 150
compounds from 12 large pharmaceutical companies, the
combined animal toxicity study of rodents and nonro-
dents accurately predicted only 50% of the human hepa-
totoxicity. Worse, at this poor level of accuracy, large
numbers of compounds that would perhaps have been
safe in human patients, but show toxicity in animals,
would be removed from development without going for-
ward into human trials [27]. The toxicity of the other
approximately 50% of compounds whose toxicity could
not be predicted was attributed to 'idiosyncratic human
hepatotoxicity, that cannot be detected by conventional
animal toxicity studies.' It has long been widely known
that mechanisms for toxicity are frequently quite different
between species; yet, animal testing remains the 'gold
standard' for historical reasons. The FDA and other regu-
latory agencies are in the process of evaluating alternatives
to animal testing, with the aim of developing models that
are truly predictive of human mechanisms of toxicity and
limiting in vivo toxicology testing.
The ADMET feedback loop
As discussed above, ADMET studies have historically
focused on in vivo assays. These are, however, time- and
resource-intensive, and are generally low throughput,
which caused them to be put off until later in the develop-
ment process, when more resources are released to studyBMC Neurology 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2377/9/S1/S1
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the few molecules that have advanced to this advanced
stage. With the advent of in vitro high-throughput screen-
ing, molecular biology and miniaturization technologies
in the 1990s, early ADMET assays were developed to pre-
dict in vivo animal and human results, at a level of cost-
effectiveness appropriate for the discovery stage. This pro-
duced a major advance in the science of ADMET, and has
created a new norm that drug-discovery programs follow
in advancing compounds from hit to lead, from lead to
advanced lead, and on to nominated clinical candidates.
Now, early in the discovery phase, using human enzymes
and human-origin cells, drug-discovery programs are able
to obtain highly actionable information about the drug-
likeness of their new molecules, their potential to reach
target organs, and early indications of known human
mechanisms of toxicities. ADMET assessment of varying
complexity is now routinely done on compounds that
have shown in vitro efficacy and at the same time with or
just prior to demonstrating early proof of principle in vivo.
The application of early ADMET is unique to each drug-
discovery program. The road from discovery to IND is not
a straight line. It depends on the therapeutic area, route of
administration, chemical series, and other parameters.
Correspondingly, the importance of the various ADMET
assays depends on the specifics of the drug-discovery pro-
gram. ADMET assays can also be divided into those that
are routine and those reserved for more advanced profil-
ing, with the division being a function of cost effectiveness
and the need for the specific information. For instance,
one does not normally need to know during the hit-to-
lead phase which transporters in the gastrointestinal tract
or the brain are involved in transporting the drug; how-
ever, later in the development process this issue becomes
more relevant.
In some cases the FDA has moved to require some of the
new in vitro ADMET assays. For example, in vitro drug-drug
interaction studies may now be conducted under the guid-
ance from the FDA dated September 2006. The guidance
document defines precisely how to conduct cytochrome
P450 (CYP450) inhibition and induction and P-gp inter-
action studies [28].
How should a discovery team employ early ADMET? The
answer is not simple and formulaic: it is a process. It is
useful to start from the ultimate goal and work backwards
towards discovery. The drug discovery and development
team should first define the target product profile, which
includes indication, intended patient population, route of
administration, acceptable toxicities, and ultimately will
define the drug label. Of course, the target product profile
invariably will evolve during the life of the project, but
having its major parameters established at the start helps
the team to keep their eyes on the ball and work in close
collaboration between disciplines such as biology and
chemistry, discovery and development, pre-clinical and
clinical groups. Once the target product profile is identi-
fied, then major design elements of the phase II and III
clinical trials can be outlined, which in turn lead to ques-
tions about the product's tolerable toxicity and safety,
which will then define the regulatory toxicity and safety
studies in animals, which will lead the team to the discov-
ery and preclinical-development questions to be
addressed via their specific early ADMET program.
In the discovery phase, at the beginning of this exciting
and risky journey, how does one put this information into
action? For example, if a compound has high target recep-
tor binding and biological activity in cells and in relevant
in vivo animal models, how can one maximize the chances
of it becoming a successful drug some day? A molecule
needs to cross many barriers on the way to its target. The
first barrier is seemingly simple: solubility. A solubility
screen will provide information about the NCE's solubil-
ity in fluids compatible with administration to humans.
The next barrier is chemical and metabolic stability.
Chemical stability in buffers, simulated gastric and intes-
tinal fluids, and metabolic stability in plasma, hepato-
cytes or liver microsomes of different species can be
measured to predict a compound's stability in the differ-
ent environments it will encounter in the human body on
the way to its target.
The second step is to define some of the absorption prop-
erties of the compounds. Are they likely to be bioavaila-
ble? Measurement of permeability across Caco-2 cell
monolayers is a good predictor of human oral bioavaila-
bility. For CNS drugs, assessment of BBB penetration
would come at this stage and is usually a part of lead opti-
mization campaigns. Passive BBB permeability may be
assessed using BBB-parallel artificial membrane permea-
bility assays (BBB-PAMPAs), whereas potential for active
uptake or efflux may be determined using in vivo models
or relevant in vitro BBB models expressing efflux and
influx transporters.
Measurement of binding to plasma proteins indicates the
degree of availability of the free compound in the blood
circulation. This is critical as only unbound drugs are able
to get to the target and exert their pharmacological effects.
Metabolism and drug-drug interaction issues can be
detected by screening for inhibition of CYP-450 liver
enzymes. All these assays allow chemists and biologists to
obtain actionable information early, allowing them to
gain understanding of structure-activity and structure-
property relationships.
The next step of determining whether drug-drug interac-
tions are involved is required for advanced lead optimiza-BMC Neurology 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2377/9/S1/S1
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tion. The effect of drug transporters on permeability and
the effect of drugs on transporter activity can be measured
in Caco-2 for the impact on intestinal absorption or using
relevant in vitro BBB models. P-gp interactions are partic-
ularly important for CNS drugs due to high expression of
these efflux transporters in the human BBB. Early knowl-
edge about these interactions is instrumental to the
medicinal chemistry strategy and helps drive lead optimi-
zation. In vivo toxic effects on human cells can be pre-
dicted  in vitro by measuring cytotoxicity using
mammalian cell lines or primary cells. The effect of a com-
pound on CYP450 metabolism can be identified by deter-
mining the 50% inhibitory concentration (IC50) for each
CYP450 enzyme. These relationships between the NCE
and metabolizing enzymes need to be evaluated in the
context of the human effective dose and maximum effec-
tive plasma concentrations. These human data are not
normally available at early stages of discovery, but could
be extrapolated from animal PK/PD results for com-
pounds in more advanced stages of development.
It is important to understand these transporter and
CYP450 relationships for several reasons. First, the com-
pound may affect the effective plasma concentrations of
other drugs taken concomitantly with the compound of
interest if they are metabolized by the same CYP450
enzymes (see the discussion of the terfenadine case
above). Second, if the parent drug is a CYP450 inducer, it
may increase the clearance rate of concomitantly adminis-
tered drugs that are metabolized by these CYP450
enzymes. This may result in a decrease in these drugs'
effective plasma concentrations, thus decreasing their
pharmacological effect. Third, metabolites formed via
CYP450 metabolism may be responsible for undesirable
side effects such as organ toxicity. Fourth, the metabolite
of a compound may actually be responsible for a com-
pound's efficacy, and not the parent compound. The
metabolite may even have a better efficacy, safety, and PK
profile than its parent. If so, metabolism can be exploited
to produce a better drug, which will substantially change
the medicinal chemistry strategy. Fifth, the identification
of drug-metabolizing enzymes involved in the major met-
abolic pathways of a compound helps in predicting the
probable drug-drug interactions in humans. This informa-
tion may also make human clinical trials designed to
detect drug-drug interaction unnecessary, accruing a sub-
stantial cost savings in development.
ADMET is a tool that supports overall program goals. Sel-
dom will negative results from a single ADMET assay kill
a compound or a program. Remember, the Rule of 5
requires that only three of the four conditions be met, and
even then there are exceptions. Instead, as was illustrated
above in the case of metabolism, the results are more
likely to just change the direction of the medicinal chem-
istry.
After assessing compounds in a few simple mechanistic
systems such as plasma and liver microsomal stability
screens in relevant species, one moves on to lead optimi-
zation using assays to identify potential liabilities. Finally,
at the stage of advanced lead optimization and develop-
ment, systems that are more complex are used to more
thoroughly understand a compound's metabolic fate and
absorption mechanism, and this understanding is used to
drive efficient development. As ADMET roadblocks are
discovered, which they inevitably will be, one repeats the
loop until a clear path is found (Figure 1).
Impact of ADMET
Early ADMET not only provides the data necessary for
selecting preclinical candidates, by providing crucial
information to medicinal chemists, it can also accelerate
the timelines for IND and subsequently new drug applica-
tion (NDA) submission, which means more time on the
market under patent protection and hence greater profits.
For investors, this is a major parameter. For philanthropic
organizations and from the standpoint of public policy, it
means increasing the time of clinical benefit to the public.
Data compiled by the Tufts Center for Drug Discovery
have identified that, for a typical, moderately successful
proprietary drug (US$350 million annual sales), each
day's delay equates to US$1.1 million in lost patent-pro-
tected revenues – revenues that provide the return on
investment needed to fund drug discovery [3]. Further, the
shorter the discovery and development timelines are, the
faster venture capital and angel investors can get to a
liquidity event. As drug discovery takes longer to commer-
cialize than any other form of product development, its
slowness to produce returns is a major impediment for
obtaining investment. Speeding up drug discovery and
ADMET feedback loop Figure 1
ADMET feedback loop.
ADMET Feedback Loop
ADMET is a tool that supports program goals
One ADMET assay is not going kill a compound
Start from simple mechanistic systems
Support lead optimization on few assays important for the series
Advanced lead optimization/development
As ADMET roadblocks discovered, repeat the loopBMC Neurology 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2377/9/S1/S1
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development should attract more investment in drug dis-
covery research.
ADMET technologies remain a work in progress. There are
many challenges in accurately measuring BBB penetra-
tion, which may be one of the reasons for poor human
efficacy of CNS drug candidates. Another challenge is
detection of all mechanisms of human idiosyncratic toxic-
ity. These mechanisms cause the most expensive, harmful,
and disheartening form of drug attrition – post-commer-
cialization toxicity. Progress is being made. Many idiosyn-
cratic drug reactions are due to formation of short-lived
reactive metabolites that bind covalently to cell proteins
[29], and the extent to which a compound will generate
these can now be detected before a compound reaches
human patients. Other mechanisms of human toxicity
can now also be detected early in discovery. Some of the
assays that are available to detect them will be briefly
described in the following section.
New ADMET tools
Penetrating the BBB is a challenge particular to CNS drug
discovery. Its importance is such that it needs to be
addressed first in this review. Another challenge caused by
BBB permeability is that many drugs not intended as CNS
therapeutics cause neurotoxicity, which should be
avoided. While artificial membrane permeability assays
(PAMPA and BBB-PAMPA) offer a cost-effective and high-
throughput way of screening for passively absorbed com-
pounds, they do not predict active transport in or out of
the brain.
In vitro model of human adult blood-brain barrier
Many new drugs designed to work in the CNS may show
exceptional therapeutic promise due to their high potency
at the target site, but lack general efficacy when adminis-
tered systemically. In many cases, the problem is due to
lack of penetration of the BBB, and this has become a
major problem that has impeded the discovery and devel-
opment of active CNS drugs. CEA Technologies previously
reported the development of a new co-culture-based
model of human BBB able to predict passive and active
transport of molecules into the CNS [19]. This new model
consists of primary cultures of human brain capillary
endothelial cells co-cultured with primary human glial
cells [19,30]. The advantages of this system are: it is made
of human primary culture cells; it avoids species, age and
inter-individual differences since the two cell types are
removed from the same person; and it has been shown to
express functional efflux transporters such as P-gp, MRP-
1, MRP-4, MRP-5 and breast cancer resistance protein
(BCRP).
This model shows good promise for assessment of perme-
ability of drugs and specific transport mechanisms, which
are not possible in PAMPA or other cell models due to
incomplete expression of active transporters.
One important step in the development of any in vitro
model is to cross-correlate in vitro and in vivo data in order
to validate experimental models and to assess the predic-
tive power of the techniques [31]. This human BBB model
has been validated against a 'gold standard' in vivo model
and has shown an excellent in vitro-in vivo correlation
[30,32]. In this carefully designed in vivo-in vitro correla-
tion study the authors reported the evaluation of the BBB
permeabilities of a series of compounds studied correla-
tively in vitro using a human BBB model and in vivo with
quantitative positron emission tomography (PET) imag-
ing in human subjects [19]. Six clinical PET tracers with
different molecular size ranges (Figure 2) and degree of
BBB penetration were used (two of them [18F]-FDOPA
and [18F]-FDG are ligands of amino acid and glucose
transporters, respectively). The findings demonstrate that
the in vitro co-culture model of human BBB has important
features of the BBB in vivo (low paracellular permeability,
well developed tight junctions, functional expression of
important known efflux transporters) and is suitable for
discriminating between CNS and non-CNS compounds.
To further demonstrate the relevance of the in vitro human
system, drug permeation into the human brain was evalu-
ated using PET imaging in parallel with the assessment of
drug permeability across the in vitro model of the human
BBB. In this view, in vivo plasma-brain exchange parame-
ters used for comparison were determined previously in
humans by PET using a kinetic analysis of radiotracer
binding. 2-[18F]fluoro-A-85380 and [11C]-raclopride
show absent or low cerebral uptake with a distribution
volume under 0.6, while [11C]-flumazenil, [11C]-befloxa-
tone, [18F]-FDOPA and [18F]-FDG show a cerebral uptake
with a distribution volume above 0.6. The in vitro human
BBB model discriminates the compounds in the same way
as in vivo human brain PET imaging analysis. These data
cast new light on the close relationship between in vitro
and in vivo PK data (r2 = 0.90, P < 0.001; Figure 2). Past in
vivo-in vitro studies often did not have good correlations
for substances transported into or out of the brain via
active transport. This is likely because the experiments had
been performed with models that either did not have ade-
quate expression of active human transporters (such as
PAMPA or MDCK cells) or had too high concentrations of
compounds  in vitro, which are known to saturate the
transporters. By using radioactive labeled probes and
small amounts of compounds, this problem can be
avoided.
In conclusion, this in vitro human BBB model offers great
promise of not only being developed into a reproducible
screen for passive BBB permeability, but also determining
active transport mechanisms. The model, due to its high-BMC Neurology 2009, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2377/9/S1/S1
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throughput potential, may help in testing large numbers
of compounds of pharmaceutical importance for CNS dis-
eases. Validation work is under way for this model (for
example, [32]), where activities of transporters that are
important in the BBB were assessed in a functional assay
and compared between Caco-2 and human BBB models.
Mechanisms of human toxicity
Idiosyncratic hepatotoxicity, or drug-induced liver injury,
occurs in only 1 out of about 10,000 patients. Thus, it is
usually statistically impossible to discover during clinical
trials. Yet, in spite of its name, which literally means 'rare
event with undefined mechanism', some mechanisms
have now been defined. One of these is mitochondrial
toxicity; the other is formation of reactive metabolites.
Another mechanism of human toxicity that is not limited
to the liver, but may also affect lung, spleen, and heart tis-
sues, is phospholipidosis.
Mitochondrial toxicity
Mitochondrial toxicity is increasingly being implicated in
drug-induced idiosyncratic toxicity. Many of the drugs
that have been withdrawn from the market due to organ
toxicity have been found to be mitochondrial toxicants
[33]. Mitochondrial toxicants injure mitochondria by
inhibiting respiratory complexes of the electron chain;
inhibiting or uncoupling oxidative phosphorylation;
inducing mitochondrial oxidative stress, or inhibiting
DNA replication, transcription or translation [34].
Toxicity testing of drug candidates is usually performed in
immortalized cell lines that have been adapted for rapid
growth in a reduced-oxygen atmosphere. Their metabo-
lism is often anaerobic, by means of glycolysis, despite
their having functional mitochondria and an adequate
oxygen supply. On the other hand, normal cells generate
ATP for energy consumption aerobically by mitochon-
drial oxidative phosphorylation. The anaerobic metabo-
lism of transformed cell lines makes them less sensitive to
mitochondrial toxicants, which is why mitochondrial tox-
icity is systematically underreported in toxicity testing in
these cell lines [34,35]. To address this, HepG2 and NIH/
3T3 cells can be grown in media in which glucose is
replaced by galactose [33]. This changes their metabolism
such that the respiratory substrate becomes more like that
of normal cells, so they become more sensitive to mito-
chondrial toxicants without reducing sensitivity to non-
mitochondrial toxicants (Figure 3).
Reactive metabolite formation
Another property of compounds that can cause idiosyn-
cratic toxicity is their ability to form reactive intermediates
[36]. Formation of short-lived reactive metabolites is
known to be the mechanism of toxicity of some com-
pounds, such as acetaminophen [37]. The formation of
In vitro-in vivo drug transport correlation Figure 2
In vitro-in vivo drug transport correlation. (A) Chem-
ical structures of radioligands investigated and used clini-
cally. (B) Typical imaging data. Co-registered positron 
emission tomography (PET)-magnetic resonance imaging 
(MRI) images representing the k1 (the kinetic rate con-
stant of the free ligand from the plasma to the free ligand 
compartment in the brain), obtained in human after intra-
venous injection of [11C]-befloxatone (left) and [18F]-F-A-
85380 (right). The PET images representing the k1 were 
acquired as follows. The PET image obtained at 1 minute 
post-injection (mean value between 30 and 90 s) is consid-
ered independent of receptor binding. This image (in Bq/
mL) is corrected from the vascular fraction (Fv in Bq/mL, 
considered as 4% of the total blood concentration at 1 
minute) and divided by the arterial plasma input function 
(AUC0-1 minute (area under curve) of the plasma concen-
tration, in Bq × Minutes/mL). The resulting parametric 
image, expressed in min-1, represents an index of the k1 
parameter of the radiotracer. (C)In vivo distribution vol-
ume (DV) as a function of the in vitro Pe-in (permeability 
from apical to basolateral compartment)/Pe-out (permea-
bility from basal to apical compartment) ratio (Q). The 
regression line was calculated, and correlation was esti-
mated by the two-tailed non-parametric Spearman test.
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reactive metabolites can be identified by incubating test
compounds with liver microsomes and adding glutath-
ione to trap the reactive intermediates, which are then
identified by liquid chromatography-tandem mass spec-
trometry (LC-MS/MS; Figure 4). In most programs this
assay is used to assess the bioactivation potential of a
compound. As with any ADMET assay, the bioactivation
potential of a compound is used in the context of the
whole program. Efficacy against target, clinical dose
Effect of antimycin A, a compound known to be toxic to mitochondria, and chlorpromazine on parent HepG2 cells (MITO-R,  blue) and a HepG2 cell line that has been developed to become sensitive to mitochondrial toxicants (MITO-S, red) Figure 3
Effect of antimycin A, a compound known to be toxic to mitochondria, and chlorpromazine on parent HepG2 
cells (MITO-R, blue) and a HepG2 cell line that has been developed to become sensitive to mitochondrial tox-
icants (MITO-S, red). Left-hand side, antimycin A; right-hand side, chlorpromazine.
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Formation of reactive metabolites of acetaminophen Figure 4
Formation of reactive metabolites of acetaminophen. Acetaminophen (ACET) was incubated with microsomes and 
glutathione (GSH) in the presence and absence of NADPH. An adduct of glutathione with acetaminophen was formed in the 
presence of NADPH. When NADPH was absent (no reaction control), no adduct was formed.
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amount, dose regimen, and clinical indication will need
to be considered when making decisions.
Phospholipidosis
Phospholipidosis is a lysosomal storage disorder. It can be
caused by drugs that are cationic amphiphiles [38]. The
disorder is considered to be mild, and often resolves by
itself, but drugs that cause phospholipidosis can also
cause organ damage, making phospholipidosis of concern
to the regulatory agencies [39]. A cell-based assay for
phospholipidosis has been developed [40], which
involves accumulation of a fluorescent phospholipid,
resulting in an increase of fluorescence in the lysosomes of
cells that have been treated with drugs that cause phos-
pholipidosis (Figure 5). If phospholipidosis is absent, the
phospholipid is degraded and fluorescence does not go
up. Many of these drugs are also cytotoxic, so increases in
fluorescence are normalized to cell numbers (Figure 5).
Genotoxicity
Genotoxicity of drugs is an important cause for concern to
the regulatory authorities. The FDA recommends a
number of in vitro and in vivo tests to measure the muta-
genic potential of chemical compounds, including the
Ames test in Salmonella typhimurium [41]. GreenScreen
GC, a new, high-throughput assay that links the regula-
tion of the human GADD45a gene to the production of
green fluorescent protein has become available. The assay
relies on the DNA damage-induced up-regulation of the
RAD54  gene in yeast, which is measured using a pro-
moter-green fluorescent protein fusion reporter [42]. The
test is more specific and sensitive for genotoxicity than
those currently recommended by the FDA, such as the
Ames and mouse lymphoma tests.
Current challenges and future directions
Great progress in the field of ADMET profiling has been
made in the past 15 years. This progress has decreased the
proportion of drug candidates failing in clinical trials for
ADME reasons, making it a bright spot in an otherwise
dismal picture of declining productivity in drug discovery.
The principal barrier now is the toxicity portion of
ADMET. The prediction of human-specific toxicology
must be improved.
Cell-based assays using established cell lines and co-cul-
tures have been used to determine toxicity to various
organs, but many of these cell lines have lost some of the
physiological activities present in normal cells. HepG2
cells, for instance, have greatly reduced levels of metabolic
enzymes. Primary human hepatocytes can be used, but
they are not only expensive, they suffer from high donor-
to-donor variability, and they maintain their characteris-
tics for only a short time. Three-dimensional models have
been developed for cell-based therapies, including micro-
patterned co-cultures of human liver cells that maintain
the phenotypic functions of the human liver for several
weeks [43], which should provide more accurate informa-
tion about toxicity when used in ADMET screening. This
could be extended to other organ-specific cells, leading to
development of integrated tissue models in the so-called
'human on a chip'[44]. The potential of stem cells to dif-
ferentiate into cell lines of many different lineages may be
exploited to develop human and animal stem-cell-derived
systems for major organ systems [45].
High content screening has been used for early cytotoxic-
ity measurement since 2003, and holds great promise. It
is based on automated epifluorescence microscopy and
image analysis of cells in a microtiter plate format. By
using four fluorescent dyes of different colors it is possible
to analyze multiple parameters at the single-cell level,
including morphological and biochemical parameters
that indicate pre-lethal cytotoxic effects, and represent dif-
ferent mechanisms of toxicity [46]. This method has been
optimized for hepatocytes, and is more predictive of hepa-
totoxicity than currently available methods. In the future
it could be applied to cells of other organs.
Drug-induced phospholipidosis is determined by measuring  the accumulation of a fluorescent phospholipid in cells  treated with increasing drug concentrations Figure 5
Drug-induced phospholipidosis is determined by 
measuring the accumulation of a fluorescent phos-
pholipid in cells treated with increasing drug concen-
trations. Fluorescence is measured and normalized to cell 
number. Fluorescence is increased in cells treated with com-
pounds that are known to cause phospholipidosis (chlorpro-
mazine, tamoxifen, amiodarone), but it is not increased in 
cells treated with a compound that is known not to cause 
phospholipidosis (acetaminophen). Conc., concentration.
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Molecular profiling is another alternative. It is defined as
any combination or individual application of mRNA
expression, proteomic, toxicogenomic, or metabolomic
measurements that characterize the state of a tissue [47].
This approach has been applied in an attempt to develop
profiles or signatures of certain toxicities. Molecular pro-
files, in conjunction with agents that specifically perturb
cellular systems, have been used to identify patterns of
changes in gene expression and other parameters at sub-
toxic drug concentrations that might be predictive of
hepatotoxicity, including idiosyncratic hepatotoxicity
[48]. In the future, larger data sets, high-throughput gene
disruptions, and more-diverse profiling data will lead to
more-detailed knowledge of disease pathways, which will
facilitate making target choices and constructing detailed
models of cellular systems for use in ADMET screening to
identify toxic compounds early in the discovery process.
The combination of in silico, in vitro, and in vivo methods
and models into multiple content data bases, data min-
ing, and predictive modeling algorithms, visualization
tools, and high-throughput data-analysis solutions can be
integrated to predict systems' ADMET properties. Such
models are starting to be built and will be widely available
in a decade or so [39]. The use of these tools will lead to a
greater understanding of the interactions of drugs with
their targets and prediction of their toxicities.
Hence, in the foreseeable future we can look forward to
not only a decrease in late-stage development failures and
withdrawals of marketed drugs, but also faster timelines
from discovery to market, and reduced development costs
through the reduction of late-stage failures.
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